Tonix doses first patient in FOCUS study of intranasal oxytocin for AVP-D at MGH

Tonix Pharmaceuticals Holding Corp.

First patient dosed in FOCUS study at Massachusetts General Hospital for arginine-vasopressin deficiency (AVP-D).
Randomized, double-blind, placebo-controlled crossover pilot evaluating TNX-2900 (6 IU) and TNX-1900 (24 IU).
Primary endpoints: markers of anxiety, depression, and socioemotional functioning; exploratory 2-week replacement on mental health.
Study aims to generate preliminary data for future oxytocin replacement therapy in AVP-D.
TNX-1900/TNX-2900 are intranasal Mg2+-potentiated oxytocin formulations in development for multiple conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.